Aptus Pharma
BSE 544529
4 stories, newest first.
- Aptus Pharma reports H1 2026-27 revenue of ₹48.92 crore, targets own manufacturing, exports and Pan-India reach by 2029
- Aptus Pharma to host Q2 FY27 earnings conference call on October 26, 2026 at 5:00 PM IST
- Board approved unaudited H1 results; auditors' limited review finds no material misstatement
- Board meeting on 20 October 2026 to consider half-year results; trading window closed
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.